Condition

Lymph Node Metastases

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 18 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18
Recruiting4
Common interventions24
Lead sponsors shown15
Advertisement

Clinical trials

18 shown
Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant ChemotherapyNCT04744506 · 2024-11-30
RECRUITING
Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy PatientsNCT05000827 · 2021-07-28
RECRUITING
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast CancerNCT04671511 · 2021-03-30
RECRUITING
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast CancerNCT04486495 · 2020-07-16
RECRUITING
Axillary Lymph Node Tattoo Marking StudyNCT04947917 · 2021-12-29
TERMINATED
Survival Impact of Internal Mammary or Supraclavicular LymphadenectomyNCT05005650 · 2021-06-01
COMPLETED
Radio Guided Lymph Node Dissection in Oligometastatic Prostate Cancer PatientsNCT04300673 · 2020-09-01
UNKNOWN
Lymphadenectomy in NSCLC With and Without Adjuvant TherapyNCT04419935 · 2020-05-13
UNKNOWN
Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast CancerNCT04322331 · 2020-05-01
UNKNOWN
Use of Indocyanine Green During Pelvic Lymph Node Dissection in Prostate Cancer.NCT04882618 · 2019-11-08
UNKNOWN
Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)NCT03216551 · 2019-03-14
COMPLETED
Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes MetastasisNCT04137406 · 2019-01-01
UNKNOWN
To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph NodesNCT03715686 · 2018-10-20
UNKNOWN
A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast CancerNCT03280134 · 2018-10-15
UNKNOWN
Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 FractionsNCT03280719 · 2017-09-15
COMPLETED
Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRINCT03223064 · 2016-12-30
UNKNOWN
Persistant Organics Pollutants in Breast Cancer.NCT03788187 · 2013-08-01
COMPLETED
SBRT for Oligometastatic Lymph Node Recurrence in Prostate Cancer: a Single Institution ExperienceNCT03604211 · 2010-01-01
COMPLETED

Common interventions

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

Leading sponsors

Trial status mix

UNKNOWN8
COMPLETED5
RECRUITING4
TERMINATED1

Phase mix

NA9
PHASE11
PHASE21
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.